Celldex Therapeutics Current Ratio 2010-2022 | CLDX

Celldex Therapeutics current ratio from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Celldex Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $0.34B $0.02B 20.54
2022-06-30 $0.37B $0.03B 12.29
2022-03-31 $0.39B $0.02B 26.83
2021-12-31 $0.41B $0.02B 24.86
2021-09-30 $0.43B $0.01B 30.09
2021-06-30 $0.17B $0.01B 11.57
2021-03-31 $0.18B $0.02B 10.69
2020-12-31 $0.20B $0.01B 13.93
2020-09-30 $0.20B $0.01B 16.63
2020-06-30 $0.21B $0.01B 19.28
2020-03-31 $0.06B $0.01B 5.12
2019-12-31 $0.07B $0.01B 5.73
2019-09-30 $0.08B $0.01B 6.32
2019-06-30 $0.08B $0.01B 7.33
2019-03-31 $0.09B $0.01B 7.41
2018-12-31 $0.10B $0.01B 7.86
2018-09-30 $0.11B $0.02B 6.59
2018-06-30 $0.12B $0.02B 6.02
2018-03-31 $0.13B $0.02B 5.45
2017-12-31 $0.15B $0.03B 5.22
2017-09-30 $0.15B $0.03B 5.91
2017-06-30 $0.16B $0.03B 5.56
2017-03-31 $0.17B $0.03B 6.42
2016-12-31 $0.20B $0.04B 5.55
2016-09-30 $0.21B $0.02B 11.26
2016-06-30 $0.23B $0.02B 11.44
2016-03-31 $0.26B $0.03B 10.31
2015-12-31 $0.30B $0.03B 9.75
2015-09-30 $0.31B $0.02B 13.09
2015-06-30 $0.34B $0.03B 12.72
2015-03-31 $0.36B $0.02B 17.22
2014-12-31 $0.21B $0.02B 8.37
2014-09-30 $0.23B $0.02B 10.63
2014-06-30 $0.26B $0.02B 12.06
2014-03-31 $0.28B $0.02B 14.19
2013-12-31 $0.31B $0.02B 15.00
2013-09-30 $0.14B $0.02B 8.33
2013-06-30 $0.16B $0.01B 12.51
2013-03-31 $0.18B $0.02B 10.06
2012-12-31 $0.09B $0.02B 4.81
2012-09-30 $0.08B $0.02B 5.21
2012-06-30 $0.08B $0.01B 6.39
2012-03-31 $0.09B $0.01B 7.51
2011-12-31 $0.06B $0.01B 3.83
2011-09-30 $0.06B $0.01B 5.97
2011-06-30 $0.07B $0.01B 7.04
2011-03-31 $0.05B $0.01B 5.18
2010-12-31 $0.06B $0.02B 3.12
2010-09-30 $0.06B $0.02B 2.54
2010-06-30 $0.07B $0.02B 2.88
2010-03-31 $0.08B $0.03B 3.15
2009-12-31 $0.08B $0.01B 5.83
2009-09-30 $0.03B $0.01B 1.99
2009-06-30 $0.03B $0.01B 2.61
2009-03-31 $0.04B $0.01B 2.98
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.171B $0.005B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00